APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease

Probably not a substantial claim: may not pass S3 (load-bearing).

Even in homozygous APOE2/2 mice, prior reports have been inconsistent regarding further reductions in amyloid pathology compared with APOE3/3.

“Even in homozygous APOE2/2 mice, prior reports have been inconsistent regarding further reductions in amyloid pathology compared with APOE3/3 , re fl ecting ongoing debate 34,48,49 .”

• cites [34] 34. Castellano, J. M. et al. Human apoE isoforms differentially regulate brain amyloidβ peptide clearance. Sci. Transl. Med 3 , 89ra57 (2011). sourceDisputed

  The Introduction (page unavailable) says this paper and others reported amyloid plaque deposition in the order E4 > E3 > E2 in APP-transgenic mice; the Discussion likewise describes its E4 > E3 > E2 finding as extending previous reports. The Discussion’s mention of conflicting studies concerns brain apoE concentrations, not whether E2 mice have less amyloid pathology than E3 mice. (LLM, conf=0.85)

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured
• cites [48] 48. Tai, L. M. et al. EFAD transgenic mice as a human APOE relevant preclinical model of Alzheimer ' s disease. J. Lipid Res 58 , 1733 -1755 (2017). sourcePartly supported

  In “APOE modulated AD symptoms exhibited in EFAD mice” (page unavailable), the paper reports equal E2FAD and E3FAD plaque measures and Aβ42 levels, supporting the point that APOE2/2 does not consistently show a further reduction in this model. It does not establish that prior mouse reports were inconsistent: its discussion of an “apparently contradictory literature” concerns human APOE2 genotypes and underpowered cohort studies. (LLM, conf=0.81)

  Experimental — accuracy not yet measured
• cites [49] 49. Bales, K. R. et al. Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J. Neurosci. 29 , 6771 -6779 (2009). sourceNot checked — no full text of the source

May combine two claims.

Amyloid PET imaging results remain inconsistent, with some studies reporting attenuated or delayed amyloid deposition in APOE2/4 individuals relative to APOE3/4, whereas others have reported no significant difference between these genotypes.

“Amyloid PET imaging results remain inconsistent, with some studies reporting attenuated or delayed amyloid deposition in APOE2/ 4 individuals relative to APOE3/4 44,45 , whereas others have reported no signi fi cant difference between these genotypes 46 .”

• cites [44] 44. Insel, P. S., Hansson, O. & Mattsson-Carlgren, N. Association between apolipoprotein E ε 2 vs ε 4, age, and β -amyloid in adults without cognitive impairment. JAMA Neurol. 78 , 229 -235 (2021). sourceSupported
• cites [45] 45. Jansen, W. J. et al. Prevalence estimates of amyloid abnormality across the alzheimer disease clinical spectrum. JAMA Neurol. 79 , 228 -243 (2022). sourceDisputed

  The Results section reports that PET-based amyloid abnormality prevalence was 10 percentage points higher in APOE ε3ε4 than ε2ε4 carriers (P = .001). Although it notes that a 2015 study found similar frequencies, this source's own result is a significant difference, contrary to the finding attributed to it. (LLM, conf=0.88)

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured
• cites [46] 46. Goldberg, T. E., Huey, E. D. & Devanand, D. P. Association of APOE e2 genotype with Alzheimer ' s and non-Alzheimer ' s neurodegenerative pathologies. Nat. Commun. 11 , 4727 (2020). sourcePartly supported

  The Results (‘E2/e4 genotype’; page not provided) report that all e2/e4 versus e3/e4 contrasts were nonsignificant, including contrasts involving amyloid plaques. This supports the cited no-difference finding, but the study assessed postmortem pathology, not amyloid PET imaging, so it does not establish that finding for PET results. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

May combine two claims.

APOE4 is the strongest genetic determinant of late-onset AD, increasing risk in a gene dose-dependent manner, whereas APOE2 confers substantial protection.

“APOE4 is the strongest genetic determinant of late-onset AD, increasing risk in a gene dose-dependent manner, whereas APOE2 confers substantial protection 1 -5 .”

• cites [1] 1. Corder, E. H. et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet 7 , 180 -184 (1994). sourceNot checked — no full text of the source
• cites [2] 2. William Rebeck, G., Reiter, J. S., Strickland, D. K. & Hyman, B. T. Apolipoprotein E in sporadic Alzheimer ' s disease: Allelic variation and receptor interactions. Neuron 11 , 575 -580 (1993). sourceNot checked — no full text of the source
• cites [3] 3. Yamazaki, Y., Zhao, N., Caul fi eld, T. R., Liu, C.-C. & Bu, G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat. Rev. Neurol. 15 , 501 -518 (2019). sourcePartly supported

  The Introduction (page unavailable) reports that one APOE ε4 allele raises late-onset AD risk 3–4-fold and two raise it 9–15-fold, supporting the gene-dose claim. It also says ε2 is associated with decreased risk, but does not quantify that protection; it calls APOE a major risk determinant rather than establishing ε4 as the strongest genetic determinant. (LLM, conf=0.83)

  Experimental — accuracy not yet measured
• cites [4] 4. Zhao, N., Liu, C. C., Qiao, W. & Bu, G. Apolipoprotein E, receptors, and modulation of Alzheimer ' s disease. Biol. Psychiatry 83 , 347 -357 (2018). sourcePartly supported

  The Abstract identifies APOE ε4 as the strongest genetic risk factor for late-onset Alzheimer’s disease and says ε2 is protective relative to ε3. The passages on Aβ deposition also describe a neuroprotective association for ε2. Our copy does not establish that AD risk rises with each ε4 allele or quantify the protection as substantial. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [5] 5. Farrer, L. A. et al. Effects of age, sex, and ethnicity on the association betweenapolipoprotein E genotype and Alzheimer disease. a metaanalysis. APOE and Alzheimer disease meta analysis consortium. Jama 278 , 1349 -1356 (1997). sourceNot checked — no full text of the source

May combine two claims.

APOE2/4 carriers exhibit an intermediate AD risk phenotype, with 2.7-fold higher risk than APOE3/3 but lower than APOE3/4 (6.1-fold) or APOE4/4 (31-fold).

“Limited neuropathological evidence suggests that APOE2/4 carriers exhibit an intermediate phenotype, showing a 2.7-fold higher AD risk than APOE3/3 individuals but much lower than APOE3/4 (6.1-fold) or APOE4/4 (31-fold) carriers 6 .”

• cites [6] 6. Reiman, E. M. et al. Exceptionally low likelihood of Alzheimer ' s dementia in APOE2 homozygotes from a 5000-person neuropathological study. Nat. Commun. 11 , 667 (2020). sourceSupported

May combine two claims.

APOE2 confers partial protection even in the presence of APOE4, although APOE4's deleterious effects tend to dominate.

“These data suggest that APOE2 confers partial protection even in the presence of APOE4 , although APOE4 ' s deleterious effects tend to dominate.”

• cites [6] 6. Reiman, E. M. et al. Exceptionally low likelihood of Alzheimer ' s dementia in APOE2 homozygotes from a 5000-person neuropathological study. Nat. Commun. 11 , 667 (2020). sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Oligodendrocyte dysfunction and myelin integrity have been shown to influence Aβ accumulation.

“Similarly, although oligodendrocyte dysfunction and myelin integrity have been shown to in fl uence A β accumulation 24 , gene expression patterns of oligodendrocyte-enriched transcripts did not differ signi fi cantly amonggenotypes (Fig. 2A).”

• cites [24] 24. Depp,C. et al. Myelin dysfunction drives amyloid-beta deposition in models of Alzheimer ' s disease. Nature 618 , 349 -357 (2023). sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

APOE is predominantly expressed in glial cells, particularly astrocytes and activated microglia, which play central roles in Aβ accumulation, clearance, and neuroinflammation.

“It is known that APOE is predominantly expressed in glial cells, particularly astrocytes and activated microglia, which play central roles in A β accumulation, clearance, and neuroin fl ammation 3,4 .”

• cites [3] 3. Yamazaki, Y., Zhao, N., Caul fi eld, T. R., Liu, C.-C. & Bu, G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat. Rev. Neurol. 15 , 501 -518 (2019). sourceSupported
• cites [4] 4. Zhao, N., Liu, C. C., Qiao, W. & Bu, G. Apolipoprotein E, receptors, and modulation of Alzheimer ' s disease. Biol. Psychiatry 83 , 347 -357 (2018). sourcePartly supported

  The 'Biochemical features of apoE' section says that, in the CNS, apoE is highly expressed in astrocytes and microglia, but it does not specify activated microglia. The Aβ metabolism and clearance sections describe roles for apoE and glial cells in Aβ production and clearance. The copy does not establish the sentence’s broader assertion that these cells play central roles in neuroinflammation. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Two major astrocyte activation states have been described in neurodegenerative diseases: A1 neurotoxic astrocytes and A2 neuroprotective astrocytes.

“Two major astrocyte activation states have been described in neurodegenerative diseases: A1 neurotoxic astrocytes and A2 neuroprotective astrocytes 23 .”

• cites [23] 23. Liddelow, S. A. et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541 , 481 -487 (2017). sourcePartly supported

  The Introduction describes two reactive astrocyte types, A1 and A2, and the Concluding Remarks characterize A1 as neurotoxic and A2 as promoting neuronal survival and tissue repair. But the paper reports A1 in neurodegenerative diseases while describing A2 as induced by ischemia; it does not establish both states in neurodegenerative diseases. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim.

Previous studies using homozygous APOE knock-in mice have been essential for defining isoform-specific effects of APOE2, APOE3, and APOE4.

“Previous studies using homozygous APOE knock-in mice have been essential for de fi ning isoform-speci fi c effects of APOE2 , APOE3 , and APOE4”

• cites [7] 7. Golden L. R., et al. APOE4 to APOE2 allelic switching in mice improves Alzheimer ' s disease-related metabolic signatures, neuropathology and cognition. Nat. Neurosci. 12 , 2461 -2475 (2025). sourcePartly supported

  The Methods (Animals; page unavailable) identify homozygous APOE2 and APOE4 targeted-replacement mice as controls, and the Discussion (page unavailable) describes differences between those two models. The paper does not establish that previous homozygous knock-in studies defined effects of all three isoforms, including APOE3, or characterize those studies as essential. (LLM, conf=0.83)

  Experimental — accuracy not yet measured
• cites [8] 8. Jackson, R. J. et al. APOE2 gene therapy reduces amyloid deposition and improves markers of neuroin fl ammation and neurodegeneration in a mouse model of Alzheimer's disease. Mol. Ther. 32 , 1373 -1386 (2024). sourcePartly supported

  The Introduction (page unavailable) reports that targeted-replacement animal models show different plaque deposition among APOE4, APOE3, and APOE2 carriers, supporting the claim that such models helped define isoform-specific effects. It does not specify that the mice in those previous comparisons were homozygous or characterize those studies as essential. (LLM, conf=0.82)

  Experimental — accuracy not yet measured
• cites [33] 33. Hudry, E. et al. Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Sci. Transl. Med 5 , 212ra161 (2013). sourcePartly supported

  The Discussion (page unavailable) reports that previous studies replacing murine Apoe with human APOE2, APOE3, or APOE4 found isoform-dependent differences in amyloid deposits. It does not specify that those mice were homozygous or characterize those studies as essential, so those details are not supported by our copy. (LLM, conf=0.82)

  Experimental — accuracy not yet measured
• cites [34] 34. Castellano, J. M. et al. Human apoE isoforms differentially regulate brain amyloidβ peptide clearance. Sci. Transl. Med 3 , 89ra57 (2011). sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

APOE has a core physiological function in peripheral lipid metabolism.

“We next asked whether these APOE -genotype dependent effects extend beyond the brain to peripheral lipid metabolism, a core physiological function of APOE 27 .”

• cites [27] 27. Karjalainen, J.-P. et al. The effect of apolipoprotein E polymorphism on serum metabolome -a population-based 10-year follow-up study. Sci. Rep. 9 , 458 (2019). sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

The association of the APOE4 isoform with amyloid deposition has been well established in human studies, where APOE4 carriers exhibit higher Aβ plaque burden and earlier onset of amyloid positivity compared with non-carriers.

“The association of the APOE4 isoform with amyloid deposition has been well established in human studies, where APOE4 carriers exhibit higher A β plaque burden and earlier onset of amyloid positivity compared with non-carriers 35 -37 .”

• cites [35] 35. Jansen, W. J. et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. Jama 313 , 1924 -1938 (2015). sourcePartly supported

  The Results (Prevalence of Amyloid Positivity; page not provided) report higher amyloid-positivity prevalence in APOE-ε4 carriers and an earlier age at which carriers reach 15% positivity. The paper does not establish that carriers have a higher Aβ plaque burden per person; it reports the prevalence of biomarker-defined amyloid pathology instead. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [36] 36. Morris, J. C. et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann. Neurol. 67 , 122 -131 (2010). sourcePartly supported

  The Results (Adjusted analyses; page unavailable) show greater amyloid-imaging binding in APOE4 carriers and a faster increase with age than in non-carriers, supporting higher Aβ burden. The paper does not establish that carriers become amyloid-positive at an earlier age: its references to earlier onset concern clinical dementia, while its earlier biomarker finding compares CSF Aβ42 with PET binding rather than carriers with non-carriers. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites [37] 37. Reiman, E. M. et al. Fibrillar amyloidβ burden in cognitively normal people at 3 levels of genetic risk for Alzheimer ' s disease. Proc. Natl. Acad. Sci. 106 , 6820 -6825 (2009). sourcePartly supported

  The Results and Discussion (page numbers unavailable) report greater fibrillar Aβ burden in cognitively normal APOE ε4 carriers than in noncarriers, and more carriers met the study’s PiB-positivity criterion. The study does not establish an earlier age of onset of amyloid positivity: its positivity comparison is cross-sectional, while the younger onset described in the Abstract concerns dementia, not amyloid positivity. (LLM, conf=0.89)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim. May combine two claims.

Viral APOE2 delivery, APOE2 gene therapy, and inducible APOE4 to APOE2 switching have demonstrated that increasing APOE2 expression or replacing APOE4 with APOE2 can ameliorate AD-related phenotypes.

“while viral APOE2 delivery, APOE2 gene therapy, and inducible APOE4 to APOE2 switching have demonstrated that increasing APOE2 expression or replacing APOE4 with APOE2 can ameliorate AD-related phenotypes 7,8,33,34 .”

• cites [7] 7. Golden L. R., et al. APOE4 to APOE2 allelic switching in mice improves Alzheimer ' s disease-related metabolic signatures, neuropathology and cognition. Nat. Neurosci. 12 , 2461 -2475 (2025). sourceSupported
• cites [8] 8. Jackson, R. J. et al. APOE2 gene therapy reduces amyloid deposition and improves markers of neuroin fl ammation and neurodegeneration in a mouse model of Alzheimer's disease. Mol. Ther. 32 , 1373 -1386 (2024). sourcePartly supported

  The Introduction and Discussion report that APOE2 gene therapy ameliorated amyloid, neuroinflammatory, and neurodegenerative phenotypes in an AD mouse model. They do not support the sentence’s inducible APOE4-to-APOE2 switching or replacement claim: the Discussion says APOE4 expression continued unchanged. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [33] 33. Hudry, E. et al. Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Sci. Transl. Med 5 , 212ra161 (2013). sourceSupported
• cites [34] 34. Castellano, J. M. et al. Human apoE isoforms differentially regulate brain amyloidβ peptide clearance. Sci. Transl. Med 3 , 89ra57 (2011). sourcePartly supported

  The Discussion (page unavailable) reports less amyloid deposition in mice expressing apoE2 than in those expressing apoE4, supporting the general idea that apoE2 is associated with a more favorable AD-related phenotype. But the Introduction describes mice bred to express different isoforms; this paper does not demonstrate viral APOE2 delivery, APOE2 gene therapy, or inducible switching from APOE4 to APOE2. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim. May combine two claims.

Using homozygous human APOE knock-in mice, previous work demonstrated that APOE4 promotes Aβ aggregation and impairs its clearance relative to APOE3.

“Using homozygous human APOE knock-in mice, previous work demonstrated that APOE4 promotes A β aggregation and impairs its clearance relative to APOE3 34,38,39 .”

• cites [34] 34. Castellano, J. M. et al. Human apoE isoforms differentially regulate brain amyloidβ peptide clearance. Sci. Transl. Med 3 , 89ra57 (2011). sourcePartly supported

  The Animals section describes homozygous human APOE-expressing PDAPP/TRE mice. The Results report slower Aβ clearance and greater amyloid plaque deposition in E4 mice than in E3 mice. But the Discussion says direct promotion of Aβ fibrillization was not established in these mice and notes conflicting aggregation studies, so the claimed aggregation mechanism is not demonstrated. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [38] 38. Liu, C. C. et al. ApoE4 Accelerates Early Seeding of Amyloid Pathology. Neuron 96 , 1024 -1032.e1023 (2017). sourcePartly supported

  The Results section reports that astrocytic apoE4 increased Aβ half-life while apoE3 did not affect clearance; the Discussion says apoE4 may enhance early amyloid seeding and aggregation. But this study used inducible, astrocyte-specific human apoE expression in mice retaining murine apoE, not homozygous human APOE targeted-replacement mice (Results, “Novel mouse models”; Discussion). The aggregation mechanism is presented as a likely explanation rather than directly demonstrated. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [39] 39. Deane, R. et al. apoE isoform -speci fi c disruption of amyloid β peptide clearance from mouse brain. J. Clin. Investig. 118 , 4002 -4013 (2008). sourcePartly supported

  The Abstract and Discussion report that apoE4 impairs Aβ clearance from mouse brain more than apoE3. The Introduction describes greater Aβ fibrillogenesis with apoE4 than apoE3, but cites earlier mouse-model studies for that finding; this paper does not demonstrate aggregation in homozygous human APOE knock-in mice. Its Methods describe clearance experiments in C57BL/6 mice and apoE protein prepared from astrocytes derived from knock-in mice. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

Human studies have linked APOE2 to greater CAA severity in some cohorts, and to CAA-related vasculopathic changes and hemorrhagic complications.

“However, human studies have linked APOE2 to greater CAA severity in some cohorts 52 , and to CAA-related vasculopathic changes and hemorrhagic complications 53,54 .”

• cites [52] 52. Nelson, P. T. et al. APOEε 2 and APOEε 4 correlate with increased amyloid accumulation in cerebral vasculature. J. Neuropathol. Exp. Neurol. 72 , 708 -715 (2013). sourceSupported
• cites [53] 53. Greenberg, S. M. et al. Association of apolipoprotein E epsilon2 and vasculopathy in cerebral amyloid angiopathy. Neurology 50 , 961 -965 (1998). sourceNot checked — no full text of the source
• cites [54] 54. McCarron, M. O. et al. The apolipoprotein E epsilon2 allele and the pathological features in cerebral amyloid angiopathy-related hemorrhage. J. Neuropathol. Exp. Neurol. 58 , 711 -718 (1999). sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

In humans, the APOE2/4 genotype confers an intermediate risk, higher than that of APOE3/3 but lower than APOE3/4 and APOE4/4.

“In humans, the APOE2/4 genotype confers an intermediate risk, higher than that of APOE3/3 but lower than APOE3/4 and APOE4/4 5,6 .”

• cites [5] 5. Farrer, L. A. et al. Effects of age, sex, and ethnicity on the association betweenapolipoprotein E genotype and Alzheimer disease. a metaanalysis. APOE and Alzheimer disease meta analysis consortium. Jama 278 , 1349 -1356 (1997). sourceNot checked — no full text of the source
• cites [6] 6. Reiman, E. M. et al. Exceptionally low likelihood of Alzheimer ' s dementia in APOE2 homozygotes from a 5000-person neuropathological study. Nat. Commun. 11 , 667 (2020). sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

These lipid species are known to accumulate with aging and AD.

“lipid species known to accumulate with aging and AD 32,55,56”

• cites [32] 32. Mahalakshmi, K. et al. In fl uential role of 7-Ketocholesterol in the progression of Alzheimer ' s disease. Prostaglandins Other Lipid Mediat 156 , 106582 (2021). sourceNot checked — no full text of the source
• cites [55] 55. Zhao, N. et al. Alzheimer ' s risk factors: age, APOE genotype, and sex drive distinct molecular pathways. Neuron 106 , 727 -742 e726 (2020). sourcePartly supported

  The Results section on mouse serum metabolite modules reports that acylcarnitines, particularly long-chain fatty acids, increase with aging. It does not establish that those lipid species also accumulate in AD; the Discussion instead reports lower blood phospholipids associated with progression to AD. No page numbers were provided for these passages. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [56] 56. Iriondo, A. et al. Cerebrospinal Fluid 7-ketocholesterol level is associated with amyloid-beta42 and white matter microstructure in cognitively healthy adults. J. Alzheimers Dis. 76 , 643 -656 (2020). sourcePartly supported

  The Discussion (page unavailable) reports that CSF levels of 24-OHC and 27-OHC were higher in patients with AD or MCI in previous case-control studies, and that some other oxysterols were higher in early-stage AD brains than in controls. This supports an AD-related increase for some lipid species, but the paper does not say that these species accumulate with aging. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

May combine two claims.

A recent inducible APOE4 to APOE2 allelic switching model showed that converting APOE4 to APOE2 in adult mice, particularly in astrocytes, reduces amyloid pathology and gliosis and improves cognitive outcomes on the 5xFAD background.

“Notably, a recent inducible APOE4 to APOE2 allelic switching model showed that converting APOE4 to APOE2 in adult mice, particularly in astrocytes, reduces amyloid pathology and gliosis and improves cognitive outcomes on the 5xFAD background 7 .”

• cites [7] 7. Golden L. R., et al. APOE4 to APOE2 allelic switching in mice improves Alzheimer ' s disease-related metabolic signatures, neuropathology and cognition. Nat. Neurosci. 12 , 2461 -2475 (2025). sourceSupported

May combine two claims.

APOE2 promotes plaque compaction and limits diffusion of toxic Aβ species.

“suggesting that APOE2 promotesplaquecompactionandlimitsdiffusion of toxicA β species 47 .”

• cites [47] 47. Yuan, P. et al. TREM2 haplode fi ciency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron 90 , 724 -739 (2016). sourcePartly supported

  The Results section (page not provided) finds that TREM2 deficiency reduces plaque compaction and allows Aβ fibrils to extend outward; the Discussion associates less compact fibrils with greater toxicity. But the Discussion only speculates that ApoE polymorphisms might affect the microglial barrier. It does not identify an APOE2 effect or show that APOE2 limits diffusion of toxic Aβ species. (LLM, conf=0.82)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Impaired microglial barrier formation has been shown to reduce plaque compaction and increase the exposure of surrounding neurites to fibrillar Aβ, resulting in greater neuritic dystrophy.

“In contrast, impaired microglial barrier formation has been shown to reduce plaque compaction and increase the exposure of surrounding neurites to fi brillar A β , resulting in greater neuritic dystrophy 47 .”

• cites [47] 47. Yuan, P. et al. TREM2 haplode fi ciency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron 90 , 724 -739 (2016). sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

APOE4 has been associated with altered plaque morphology, greater fibrillar amyloid deposition, and enhanced plaque-associated microglial reactivity.

“APOE4 has been associated with altered plaque morphology, greater fi brillar amyloid deposition, and enhanced plaque-associated microglialreactivity”

• cites [51] 51. Rodriguez, G. A., Tai, L. M., LaDu, M. J. & Rebeck, G. W. Human APOE4 increases microglia reactivity at A β plaques in a mouse model of A β deposition. J. Neuroin fl ammation 11 , 111 (2014). sourcePartly supported

  The Results report altered plaque morphology in E4FAD mice and increased plaque-associated microglial reactivity in deep cortical layers; they found no genotype effect on microglial reactivity in the subiculum. The Discussion says this study used a pan-specific Aβ antibody, whereas a previous study used a stain for amyloid fibrils. This paper does not establish greater fibrillar amyloid deposition specifically. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

Microglia form a critical interface between APOE genotype and amyloid pathology, mediating Aβ clearance and restricting local toxicity.

“Microglia form a critical interface between APOE genotype and amyloid pathology, mediating A β clearance and restricting local toxicity 25,40 .”

• cites [25] 25. Condello, C., Yuan, P., Schain, A. & Grutzendler, J. Microglia constitute a barrier that prevents neurotoxic proto fi brillar A β 42 hotspots around plaques. Nat. Commun. 6 , 6176 (2015). sourcePartly supported

  The Introduction describes a proposed role for microglia in Aβ clearance, and the Discussion reports that microglial coverage limits protofibrillar Aβ hotspots and neuritic damage. The paper does not establish an interface between APOE genotype and amyloid pathology, and it presents clearance as a possible mechanism rather than a demonstrated basis for the protective barrier. Page numbers are unavailable in our copy. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [40] 40. Ulrich, J. D. et al. ApoE facilitates the microglial response to amyloid plaque pathology. J. Exp. Med. 215 , 1047 -1058 (2018). sourcePartly supported

  The Introduction and the section on decreased plaque-associated microgliosis report that Apoe deficiency reduces microglial clustering around plaques, while the Introduction reports increased dystrophic neurites and suggests a protective role against local toxicity. But the Introduction attributes Aβ clearance effects to apoE, not specifically to microglia; this study compares Apoe-deficient and non-deficient mice rather than establishing effects across APOE alleles. Page numbers are not available in our copy. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

May combine two claims.

APOE3/4 mice showed numerically increased peri-plaque dystrophic neurites in the cortex, not meeting the adjusted significance threshold p<0.0167 (p=0.018).

“APOE3/4 mice showed numerically increased peri-plaque dystrophic neurites in the cortex, although the difference did not meet the adjusted signi fi cance threshold of p&lt;0.0167 ( p =0.018).”

May combine two claims.

X-34 staining was significantly increased in APOE3/4 mice, whereas APOE2/3 and APOE2/4 mice remained comparable to APOE3/3 controls.

“Consistent with these observations, X-34 staining, which measures overall fi brillar A β burden, was signi fi cantly increased in APOE3/4 mice, whereas APOE2/3 and APOE2/4 mice remained comparable to APOE3/3 controls (Fig. 1G, H).”

May combine two claims.

Cortical APOE protein abundance was reduced by ~25% in APOE3/4 mice compared to APOE3/3, whereas APOE2/3 and APOE2/4 mice exhibited similar levels to APOE3/3.

“cortical APOE abundance was reduced by ~25% in APOE3/4 mice compared to APOE3/3 , whereas APOE2/3 and APOE2/4 mice exhibited similar levels to APOE3/3 (Supplementary Fig. 1B, C).”

May combine two claims.

Immunostaining for CD13, GLUT1, and ZO-1 revealed no significant differences among APOE genotypes, indicating preserved pericyte-associated coverage, endothelial structure, and tight-junction integrity.

“Immunostaining for CD13, GLUT1, and ZO-1 revealed no signi fi cant differences among APOE genotypes, indicating preserved pericyte-associated coverage, endothelial structure, and tight-junction integrity (Supplementary Fig. 3A -D).”

May combine two claims.

Aβ40 levels were numerically higher in APOE3/4 mice across all fractions but did not meet the adjusted significance threshold p<0.0167 (TBS p=0.05; TBSX p=0.05; GDN p=0.02).

“A β 40 levels were also numerically higher in APOE3/4 mice across all fractions, although the differences did not meet the adjusted signi fi cance threshold of p &lt;0.0167 (TBS, p =0.05; TBSX, p =0.05; GDN, p =0.02).”

May combine two claims.

APOE3/4 mice exhibited significantly greater leptomeningeal CAA deposition than APOE3/3, while APOE2/3 and APOE2/4 mice showed no significant changes.

“APOE3/4 mice exhibited signi fi cantly greater CAA deposition than APOE3/3 , while APOE2/3 and APOE2/4 mice showed no signi fi cant changes (Fig. 1I, J), consistent with the pattern observed for parenchymal A β load.”

May combine two claims.

Both APOE and DAM gene expression were positively associated with amyloid burden.

“Both APOE and DAM gene expression were positively associated with amyloid burden (Supplementary Fig. 5O -BB).”

May combine two claims.

Cortical GFAP-positive astrocyte coverage was numerically higher in APOE3/4 mice, not meeting adjusted significance threshold p<0.0167 (p=0.03), whereas APOE2/3 and APOE2/4 mice displayed levels comparable to APOE3/3 controls.

“Cortical GFAP-positive astrocyte coverage was numerically higher in APOE3/4 mice, although the difference did not meet the adjusted signi fi cance threshold of p &lt;0.0167 ( p =0.03), whereas APOE2/3 and APOE2/4 mice displayed levels comparable to APOE3/3 controls (Supplementary Fig. 6C, D).”

May combine two claims.

DEPs in APOE2/3 relative to APOE3/3 (e.g., Nop56, Rps9) were modest and enriched for rRNA processing and eukaryotic translation termination and elongation, reflecting a more stable, homeostatic proteomic landscape maintained by APOE2.

“DEPs in APOE2/3 relative to APOE3/3 (e.g., Nop56, Rps9) were modest and enriched for rRNA processing and eukaryotic translation termination and elongation (Fig. 4D -F), re fl ecting a more stable, homeostatic proteomic landscape maintained by APOE2 .”

Probably not a substantial claim: may not pass S3 (load-bearing).

PCA of individual module eigengenes revealed substantial overlap among APOE genotypes and sexes across most modules.

“Principal component analysis (PCA) of individual module eigengenes revealed substantial overlap among APOE genotypes and sexes across most modules.”

May combine two claims.

The overall density of OLIG2-positive oligodendrocyte-lineage cells and BCAS1-positive newly formed or actively myelinating oligodendrocytes was similar across APOE genotypes in both brain regions, indicating APOE genotype does not substantially alter oligodendrocyte abundance or differentiation.

“Likewise, the overall density of OLIG2-positive oligodendrocyte-lineage cells and BCAS1-positive newly formed or actively myelinating oligodendrocytes was similar across APOE genotypes in both brain regions (Supplementary Fig. 8A -H), indicating that APOE genotype does not substantially alter oligodendrocyte abundance or differentiation.”

May combine two claims.

For plaque-associated microglia, females showed a pattern similar to the combined analysis, whereas the male cohort exhibited greater variability and fewer statistically significant genotype differences.

“For plaque-associated microglia, females showed a pattern similar to that observed in the combined analysis, whereas the male cohort exhibited greater variability and fewer statistically signi fi cant genotype differences (Supplementary Fig. 7C, D).”

May combine two claims.

Among 10,102 proteins detected, APOE3/4 mice exhibited the most extensive proteomic alterations, with 58 proteins upregulated and 53 downregulated relative to APOE3/3.

“Among the 10,102 proteins detected (Supplementary Data 2), differentially expressed proteins (DEPs) were determined by comparing each heterozygous group to APOE3/3 controls (Fig. 4D). Among all genotypes, APOE3/4 mice exhibited the most extensive proteomic alterations, with 58 proteins upregulated and 53 downregulated relative to APOE3/3 .”

May combine two claims.

No significant DEPs were detected in APOE2/4 mice, indicating that the overall cortical proteomic profile of APOE2/4 closely resembles that of APOE3/3.

“In contrast, APOE2/3 mice showed only minor changes (10 upregulated, 5 downregulated), and strikingly, no signi fi cant DEPs were detected in APOE2/ 4 mice (Fig. 4D), indicating that the overall cortical proteomic pro fi le of APOE2/4 closely resembles that of APOE3/3 .”

May combine two claims.

The blue immune module positively correlated with cortical Aβ peptide levels, whereas the brown synaptic module correlated negatively.

“Importantly, correlation analyses revealed that the blue immune module positively correlated with cortical A β peptide levels, whereas the brown synaptic module correlated negatively (Fig. 5J, K), linking these coordinated proteomic signatures to amyloid burden.”

May combine two claims.

Both the blue and brown modules remained largely unchanged in APOE2/3 and APOE2/4 mice.

“Both modules remained largely unchanged in APOE2/3 and APOE2/4 mice (Fig. 5A -C).”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

A modest trend toward separation of APOE3/4 female samples was observed in the blue and brown modules, although no distinct clustering was evident.

“A modest trend toward separation of APOE3/4 female samples was observed in the blue and brown modules (Supplementary Fig. 11), the two modules most strongly associated with APOE genotype, although no distinct clustering was evident.”

May combine two claims.

APOE2/4 mice, despite carrying one copy of APOE4, showed amyloid burden, fibrillar deposition, and neuritic dystrophy levels comparable to APOE3/3 controls, in contrast to exacerbated pathology in APOE3/4 mice.

“APOE2/4 mice, despite carrying one copy of APOE4 , showed amyloid burden, fi brillar deposition, and neuritic dystrophy levels comparable to APOE3/3 controls, in clear contrast to the exacerbated pathology observed in APOE3/4 mice.”

May combine two claims.

APOE3/4 mice exhibited significantly reduced microglial clustering with plaque relative to APOE3/3, whereas APOE2/3 and APOE2/4 mice maintained plaque-associated microglial engagement comparable to APOE3/3.

“APOE3/4 mice exhibited signi fi cantly reduced microglial clustering with plaque relative to APOE3/3 , whereas APOE2/3 and APOE2/4 mice maintained plaque-associated microglial engagement comparable to APOE3/3 (Fig. 2D, E).”

Probably not a substantial claim: may not pass S3 (load-bearing).

Sex-stratified analyses of MBP generally showed patterns similar to those observed in the combined cohort.

“Sex-strati fi ed analyses of MBP generally showed patterns similar to those observed in the combined cohort.”

May combine two claims.

The increase in MBP was not observed in APOE2/4 mice, whose MBP levels remained comparable to APOE3/3 controls.

“This increase was not observed in APOE2/4 mice, whose MBP levels remained comparable to APOE3/3 controls.”

May combine two claims.

Sex-stratified analyses revealed similar genotype-dependent patterns for both CD63 immunoreactivity and Nectin1 protein levels in females and males, with reduced statistical significance in some comparisons following stratification.

“Sex-strati fi ed analyses revealed similar genotype-dependent patterns for both CD63 immunoreactivity and Nectin1 protein levels in females and males (Supplementary Fig. 10A-D), with reduced statistical signi fi cance in some comparisons following strati fi cation because of the smaller sample size within each sex.”

May combine two claims.

Cd63 immunoreactivity was enriched in microglia and increased in APOE3/4 mice relative to APOE3/3 controls, consistent with enhanced lysosomal activation.

“Cd63 immunoreactivity was enriched in microglia and increased in APOE3/4 micerelative to APOE3/ 3 controls, consistent with enhanced lysosomal activation in this genotype (Fig. 4G, H).”

May combine two claims.

The brown module was downregulated and enriched for synaptic function-related pathways, including glutamatergic synapse function, synapse organization, and neuronal projection organization.

“Conversely, the brown module was downregulated (Fig. 5A, C) and was enriched for synaptic functionrelated pathways, including glutamatergic synapse function, synapse organization, and neuronal projection organization (Fig. 5G -I).”

May combine two claims.

APOE protein levels were elevated in APOE3/4 mice but remained comparable in APOE2/3 and APOE2/4 mice, relative to APOE3/3.

“APOE protein levels followed a similar pattern: they were elevated in APOE3/4 mice but remained comparable in APOE2/3 and APOE2/4 mice, relative to APOE3/3 (Fig. 4C).”

May combine two claims.

Iba1-positive microglia densities were similar across genotypes, indicating APOE genotype primarily affects microglial activation state rather than cell number.

“Quanti fi cation of Iba1-positive microglia revealed similar overall densities across genotypes (Supplementary Fig. 6A, B), indicating that APOE genotype primarily affects microglial activation state rather than cell number.”

Probably not a substantial claim: may not pass S3 (load-bearing).

WGCNA across all samples revealed 19 modules.

“To identify co-regulated protein networks, we performed weighted gene co-expression network analysis (WGCNA) across all samples, revealing 19 modules (Supplementary Data 2).”

May combine two claims.

Both Cd63 immunoreactivity and Nectin1 protein levels in APOE2/3 and APOE2/4 mice remained comparable to those in APOE3/3 controls.

“Both Cd63 immunoreactivity and Nectin1 protein levels in APOE2/3 and APOE2/4 mice remained comparable to those in APOE3/3 controls (Fig. 4G -J).”

May combine two claims.

In APOE2/4 mice, these phenotypes were less pronounced and more closely resembled those observed in APOE3/3 and APOE2/3 mice.

“In APOE2/4 mice, these phenotypes were less pronounced and more closely resembled those observed in APOE3/3 and APOE2/3 mice.”

May combine two claims.

Neither APOE2/3 nor APOE2/4 mice exhibited significant alterations in these pathways.

“In contrast, neither APOE2/3 nor APOE2/4 mice exhibited signi fi cant alterations in these pathways.”

May combine two claims.

Levels of Aβ peptides including Aβ6-16 and Aβ17-28 were significantly elevated in APOE3/4 mice compared with APOE3/3 controls, whereas APOE2/3 and APOE2/4 mice showed no significant changes.

“Consistent with prior results, levels of A β peptides, including A β 6-16 and A β 17-28, were signi fi cantly elevated in APOE3/4 mice compared with APOE3/3 controls, whereas APOE2/3 and APOE2/4 mice showed no signi fi cant changes (Fig. 4A, B).”

May combine two claims.

Plasma lipidomics revealed shared alterations in APOE3/4 and APOE2/4 mice, with distinct signatures in APOE2/3 mice.

“Plasma lipidomics revealed shared alterations in APOE3/4 and APOE2/4 mice, with distinct signatures in APOE2/3 mice.”

The quote only partly states this claim.

APOE2/3 mice displayed selective decreases in long-chain acyl-carnitines (CAR 22:3, CAR 22:4-OH), lysophosphatidylethanolamine (LPE 20:1), and the oxysterol 7-keto-27-hydroxycholesterol compared with APOE3/3.

“In contrast, APOE2/3 mice displayed selective decreases in long-chain acyl-carnitines (CAR 22:3, CAR 22:4-OH), lysophosphatidylethanolamine (LPE 20:1), and the oxysterol 7-keto-27-hydroxycholesterol”

May combine two claims.

In the present study, APOE2-containing genotypes showed a greater relative proportion of compact plaques but lower overall fibrillar amyloid burden than APOE3/4 mice.

“In the present study, APOE2 -containing genotypes showed a greater relative proportion of compact plaques but lower overall fi brillar amyloid burden than APOE3/4 mice.”

May combine two claims.

Microglia in APOE2/4 mice maintained balanced activation and robust plaque clustering, similar to APOE3/3 controls.

“Correspondingly, microglia in APOE2/4 mice maintained balanced activation and robust plaque clustering, similar to APOE3/3 controls.”

May combine two claims.

APOE2/4 mice exhibited amyloid plaque burden, fibrillar Aβ deposition, and leptomeningeal CAA levels comparable to APOE3/3 littermates.

“Interestingly, APOE2/4 mice exhibited amyloid plaque burden, fi brillar A β deposition, and leptomeningeal CAA levels comparable to APOE3/3 littermates”

May combine two claims.

Plaques in APOE2/4 mice were smaller and more compact, resembling those in APOE2/3 animals.

“Plaques in APOE2/4 mice were smaller and more compact, resembling those in APOE2/3 animals”

May combine two claims.

Although plasma FFAs were positively associated with brain Aβ burden, brain FFAs showed no corresponding relationship.

“Although plasma FFAs were positively associated with brain A β burden, brain FFAs showed no corresponding relationship.”

Probably not a substantial claim: may not pass S3 (load-bearing).

The generated APOE2/3, APOE3/4, APOE2/4, and APOE3/3 littermates collectively represent ~97% of human APOE genotypes.

“producing littermates that collectively represent ~97% of human APOE genotypes.”

May combine two claims.

Aβ42 accumulation is elevated in APOE3/4 mice, whereas Aβ40 shows a similar but nonsignificant numerical trend.

“These fi ndings indicate that A β 42 accumulation is elevated in APOE3/4 mice, whereas A β 40 shows a similar but nonsigni fi cant numerical trend.”

May combine two claims.

APOE3/4 mice exhibit increased amyloid accumulation and dystrophic neurites compared with APOE3/3 controls, indicating that the APOE4 allele remains detrimental in the presence of APOE3.

“Collectively, these fi ndings demonstrate that APOE3/4 mice exhibit increased amyloid accumulation and dystrophic neurites compared with APOE3/3 controls, indicating that the APOE4 allele remains detrimental in the presence of APOE3 .”

May combine two claims.

Although several comparisons no longer reached statistical significance after sex stratification, the direction and magnitude of effects were largely preserved, consistent with reduced statistical power from smaller sample size within each sex.

“Although several comparisons no longer reached statistical signi fi cance after strati fi cation, the direction and magnitude of the effects were largely preserved, consistent with the reduced statistical power resulting from the smaller sample size within each sex.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

APOE3/3 is the most common genotype (~60-65%), APOE2/3 ~10%, and APOE3/4 ~20%, far more prevalent than APOE2/2 (~0.2%) or APOE4/4 (~2%).

“where APOE3/3 ( ~ 60-65%) is most common and APOE2/3 ( ~ 10%) and APOE3/4 ( ~ 20%) are far more prevalent than either homozygous APOE2/2 ( ~ 0.2%) or APOE4/4 ( ~ 2%) individuals 9 .”

• cites [9] 9. 2020 Alzheimer ' s disease facts and fi gures. Alzheimers Dement , (2020).Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

Neither the Aβ42 nor Aβ40 pattern was observed in APOE2/4 mice, suggesting APOE2 modifies APOE4-associated molecular changes in the heterozygous state.

“Neither pattern was observed in APOE2/4 mice, suggesting that APOE2 modi fi es APOE4 -associated molecular changes in the heterozygous state.”

Classified as probably not a substantial claim.

All primary analyses were performed using linear models with sex included as a covariate.

“all primary analyses were performed using linear models with sex included as a covariate to maximize statistical power while accounting for sex-dependent effects.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Some genotype-dependent differences were more apparent in one sex than the other, but reduced sample size limited statistical power, and these analyses should not be interpreted as evidence for sex-dependent genotype effects.

“While some genotypedependent differences were more apparent in one sex than the other, the reduced sample size following strati fi cation limited statistical power, and these analyses should not be interpreted as evidence for sex-dependent genotype effects (Supplementary Fig. 9A-D).”

Probably not a substantial claim: may not pass S3 (load-bearing).

Microglial activation is a hallmark of AD pathology.

“Microglial activation is a hallmark of AD pathology 20 .”

• cites [20] 20. Deczkowska, A. et al. Disease-associated microglia: a universal immune sensor of neurodegeneration. Cell 173 , 1073 -1081 (2018). sourceNot checked — no full text of the source

May combine two claims.

APOE2 may attenuate amyloid-promoting and neurotoxic effects of APOE4 in vivo, revealing a protective influence of APOE2 within the heterozygous context.

“Together, these results suggest that APOE2 may attenuate amyloidpromoting and neurotoxic effects of APOE4 in vivo, revealing a protective in fl uence of APOE2 within the heterozygous context.”

May combine two claims.

APOE2 increased MBP immunoreactivity in APOE2/3 mice, whereas this effect was not observed in APOE2/4 mice, suggesting differential effects of APOE allele interactions on microglial activation and myelin biology.

“APOE2 also increased MBP immunoreactivity in APOE2/3 mice, whereas this effect was not observed in APOE2/4 mice, suggesting differential effects of APOE allele interactions on microglial activation and myelin biology.”

May combine two claims.

Although the APOE3/4 vs APOE3/3 comparison no longer reached statistical significance in females after stratification, the direction and magnitude remained similar, consistent with reduced power.

“Although the comparison between APOE3/4 and APOE3/3 mice no longer reached statistical signi fi cance in females after strati fi cation, the direction and magnitude of the effect remained similar, consistent with reduced statistical power resulting from the smaller sample size within each sex.”

May combine two claims.

APOE4 is associated with increased DAM gene expression, reduced plaque-associated microglial interactions, and greater Aβ accumulation.

“Together, these fi ndings demonstrate that APOE4 is associated with increased DAM gene expression, reduced plaque-associated microglial interactions, and greater A β accumulation.”

Probably not a substantial claim: may not pass S3 (load-bearing).

A modest degree of amyloid-associated astrogliosis may be present.

“This indicates that, although A1 and A2 astrocyte subtype gene signatures were not signi fi cantly altered, a modest degree of amyloid-associated astrogliosis may be present.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Subgroup analyses after sex stratification should be interpreted with caution and do not provide conclusive evidence for sex-dependent effects of APOE genotype.

“Given the reduced sample size following sex strati fi cation, these subgroup analyses should be interpreted with caution and do not provide conclusive evidence for sex-dependent effects of APOE genotype.”

May combine two claims.

These findings define allele interaction-dependent effects of APOE on brain and systemic phenotypes and provide a framework for understanding the biological consequences of the APOE2/4 genotype.

“These fi ndings de fi ne allele interaction-dependent effects of APOE on brain and systemic phenotypes and provide a framework for understanding the biological consequences of the APOE2/4 genotype.”

May combine two claims.

APOE2, either alone or in combination with APOE4, maintains molecular homeostasis, effectively attenuating APOE4-driven inflammatory and synaptic disruption.

“In contrast, APOE2 , either alone or in combination with APOE4 , maintains molecular homeostasis, effectively attenuating APOE4 -driven in fl ammatory and synaptic disruption.”

Classified as probably not a substantial claim.

These approaches do not directly address how two different endogenous APOE alleles interact when naturally co-expressed throughout life.

“However, these approaches do not directly address how two different endogenous APOE alleles interact whennaturally co-expressed throughout life.”

May combine two claims.

APOE2 potentially enhances β-oxidation and mitigates lipid peroxidation in the absence of APOE4.

“potentially indicating that APOE2 enhances β -oxidation and mitigates lipid peroxidation in the absence of APOE4”

Probably not a substantial claim: may not pass S3 (load-bearing).

APOE2 is potentially associated with a shift in TAG metabolism or neutral lipid storage.

“potentially indicating a APOE2 -associated shift in TAG metabolism or neutral lipid storage.”

Classified as probably not a substantial claim.

The specific influence of APOE2/4 on amyloid pathology remains uncertain.

“However, its speci fi c in fl uence on amyloid pathology remains uncertain.”

May combine two claims.

APOE genotype influences both plaque architecture and amyloid load.

“These fi ndings indicate that APOE genotype in fl uences both plaque architecture and amyloid load”

Probably not a substantial claim: may not pass S3 (load-bearing).

APOE2 may influence protein synthesis or proteostatic regulation in the brain.

“raises the possibility that APOE2 in fl uences protein synthesis or proteostatic regulation in the brain.”

May combine two claims.

APOE2/4 cortices show preserved homeostasis and a lack of inflammatory remodeling.

“indicating preserved homeostasis and a lack of in fl ammatory remodeling.”

Probably not a substantial claim: may not pass S3 (load-bearing).

The absence of this enhancement in APOE2/4 mice raises the possibility that APOE4 limits APOE2-mediated myelin support.

“Theabsenceofthisenhancementin APOE2/4 miceraises the possibility that APOE4 limits APOE2 -mediated myelin support”

Probably not a substantial claim: may not pass S3 (load-bearing).

This similarity suggests that this effect might be related to the APOE4 allele.

“This similarity suggests that this effect might be related to the APOE4 allele”

Probably not a substantial claim: may not pass S3 (load-bearing).

Fatty acids detected through the TAG parent ion-neutral loss relationship represent esterified fatty acyl chains within TAG rather than free fatty acids.

“Thus, fatty acids detected through this parent ion -neutral loss relationship represent esteri fi ed fatty acyl chains within TAG rather than free fatty acids 78 .”

• cites [78] 78. Han, X. &amp; Gross, R. W. Quantitative analysis and molecular species fi ngerprinting of triacylglyceride molecular species directly from lipid extracts of biological samples by electrospray ionization tandem mass spectrometry. Anal. Biochem 295 , 88 -100 (2001). sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

Samples Q4292 and Q4604 were removed from downstream analyses as outliers based on principal component analysis.

“Samples Q4292 and Q4604 were removed from downstream analyses as outliers based on Principle Component Analysis (PCA).”

Probably not a substantial claim: may not pass S3 (load-bearing).

The experiments in this study were randomized.

“The experiments were randomized, and investigators were blinded to allocation during experiments and outcome assessment.”

Classified as probably not a substantial claim. The quote only partly states this claim.

Multiple testing in the differential peptide, gene expression and lipid analyses was controlled using the Benjamini-Hochberg procedure at a false discovery rate threshold of 0.05.

“The BenjaminiHochberg (BH) procedure was applied to adjust for multiple testing.”

• Also stated in: § NanoString data analysis · p. 16 · plain

  “p values were adjusted by the Benjamini-Hochberg method to control the false discovery rate (FDR &lt; 0.05).”

• Also stated in: § Lipidomic data analysis · p. 16 · plain

  “signi fi cance was determined by the Benjamini-Hochberg FDR method (FDR&lt;0.05).”

Probably not a substantial claim: may not pass S3 (load-bearing).

Peptide-spectrum matches were filtered based on match quality scores and mass measurement precision to achieve a protein identification false discovery rate under 1%.

“The resulting peptide-spectrum matches (PSMs) were fi ltered based on match quality scores and mass measurement precision to achieve protein identi fi cation FDR under 1%.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Our study does not distinguish whether the reduced amyloid pathology in APOE2/4 mice reflects protective functions conferred by APOE2, reduced APOE4-associated activity, or both.

“Second, although APOE2/4 mice exhibited reduced amyloid pathology relative to APOE3/4 mice, our study does not distinguish whether this re fl ects protective functions conferred by APOE2 , reduced APOE4 -associated activity, or both.”

Probably not a substantial claim: may not pass S3 (load-bearing).

The present study was not specifically powered to detect genotype-by-sex interactions.

“Third, the present study was not speci fi cally powered to detect genotype-by-sex interactions.”

May combine two claims.

Our study provides in vivo evidence that the protective APOE2 allele can attenuate the deleterious effects of APOE4 across multiple biological levels, including amyloid deposition, microglial activation and responses, and molecular proteomic profiles in the APOE2/4 genotype.

“In summary, our study provides in vivo evidence that the protective APOE2 allele can attenuate the deleterious effects of APOE4 across multiple biological levels, including amyloid deposition, microglial activation and responses, and molecular proteomic pro fi les in the APOE2/4 genotype.”

Classified as probably not a substantial claim.

All staining, imaging, and quantification were conducted by investigators blinded to sample identity and demographic information.

“All staining, imaging, and quanti fi cation were conducted by investigators blinded to sample identity and demographic information.”

Probably not a substantial claim: may not pass S3 (load-bearing).

No statistical method was used to predetermine the sample size of the study.

“Nostatistical method was used to predetermine sample size.”

May combine two claims.

These findings suggest that circulating lipid signatures may reflect systemic processes, such as hepatic metabolism or lipoprotein remodeling, whereas brain CE accumulation may be more closely linked to local amyloid pathology.

“These fi ndings suggest that circulating lipid signatures may re fl ect systemic processes, such as hepatic metabolism or lipoprotein remodeling, whereas brain CE accumulation may be more closely linked to local amyloid pathology.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Previous in vitro studies have demonstrated that FFAs can stimulate the assembly of Aβ filaments.

“Previous in vitro studies have demonstrated that FFAs can stimulate the assembly of A β fi laments 57 .”

• cites [57] 57. Wilson, D. M. &amp; Binder, L. I. Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer ' s disease. Am. J. Pathol. 150 , 2181 -2195 (1997).Not checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

Although littermate-controlled breeding minimized genetic background effects, the parent-of-origin inheritance of the APOE alleles and the 5xFAD transgene was not specifically controlled in this study.

“In addition, although littermate-controlled breeding minimized genetic background effects, the parent-of-origin inheritance of the APOE alleles and the 5xFAD transgene was not speci fi cally controlled in this study.”

Classified as probably not a substantial claim.

P values for the three pairwise APOE genotype comparisons were adjusted using the Bonferroni correction, with significance set at less than 0.0167.

“P values were adjusted using the Bonferroni correction, with signi fi cance set at &lt; 0.0167 (0.05/3) for three pairwise comparisons.”

Probably not a substantial claim: may not pass S3 (load-bearing). The quote only partly states this claim.

In the study's analyses of proteomic, transcriptomic and lipidomic data, APOE genotype effects were estimated while adjusting for sex as a covariate.

“to evaluate the effects of APOE genotype while adjusting for sex.”

• Also stated in: § Proteomic data analysis · p. 15 · plain

  “Peptide abundances between each pair of APOE genotypes were compared using Analyses of Variance models (ANOVA) while adjusting for sex.”

• Also stated in: § NanoString data analysis · p. 16 · plain

  “A linear model was constructed using the formula ~0 + APOE Genotype + Sex, where genotype effects were estimated while adjusting for sex as a covariate.”

Probably not a substantial claim: may not pass S3 (load-bearing).

A target-decoy search strategy was used to estimate the false discovery rate in the proteomic database search.

“A target-decoy search strategy enabled FDRestimation 70 .”

• cites [70] 70. Elias, J. E. &amp; Gygi, S. P. Target-decoy search strategy for increased confi dence in large-scale protein identi fi cations by mass spectrometry. Nat. Methods 4 , 207 -214 (2007). sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

All animal procedures were approved by the Mayo Clinic IACUC under protocol number A00003820-18-R24.

“All animal procedures were approved by the Mayo Clinic Institutional Animal Care and Use Committee (IACUC) under protocol number A00003820-18-R24”

Probably not a substantial claim: may not pass S3 (load-bearing).

Investigators were blinded to allocation during experiments and outcome assessment.

“The experiments were randomized, and investigators were blinded to allocation during experiments and outcome assessment.”